Medicine
Ninlaro 3 mg capsule
Ninlaro 3 mg capsule is a prescription medicine containing Ixazomib for oral use, marketed by Takeda Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Store NINLARO at room temperature. Do not store above 30°C…
Key facts
- Active ingredient (INN)
- Ixazomib
- Brand
- Ninlaro
- Strength
- 3 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 1 capsule, 1 blister pack
- Marketing authorisation holder
- Takeda Pharmaceuticals
- Manufacturer
- Takeda Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Store NINLARO at room temperature. Do not store above 30°C (86°F). Store capsules in original packaging until immediately prior to use.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XG03 Ixazomib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 November 2015
- Identifiers
- RxCUI 1723757, 1723763, 1723765 +3DailyMed set ID 038f2461-834b-4488-9ebd-863c83eef5a7NDC 63020-390Application NDA208462
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 capsule in 1 blister pack | 63020-390-01 | Takeda Pharmaceuticals | 20 November 2015 |
| 1 blister pack in 1 carton / 3 capsule in 1 blister pack | 63020-390-02 | Takeda Pharmaceuticals | 20 November 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Ixazomib
Clinical summary
Ixazomib is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. It is available as capsules for oral use. MedsAcross supplies Ixazomib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about IxazomibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- NINLARO prescribing information (Takeda Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Ninlaro: European public assessment report (EPAR) · European Medicines Agency
Need Ninlaro 3 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.